All News
Filter News
Found 631 articles
-
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
10/31/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7, 2023.
-
Rigel Announces Presentation at the Upcoming IDWeek 2023
10/11/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors at IDWeek 2023 being held October 11-15, 2023.
-
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - October 06, 2023
10/6/2023
Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
10/4/2023
Alpine Immune Sciences, Inc. today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023.
-
Athersys Director Jane Wasman Appointed Board Chair
10/2/2023
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.
-
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
9/25/2023
Castle Biosciences, Inc. today announced that the Company will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.
-
Rigel to Present at the 2023 Cantor Global Healthcare Conference
9/20/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m. ET in New York, NY.
-
Rigel to Participate in Upcoming September 2023 Investor Conferences
8/30/2023
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September.
-
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
8/1/2023
Rigel Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
7/25/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1, 2023.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 05, 2023
7/5/2023
Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
6/7/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
-
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
6/6/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and positioning of REZLIDHIA® (olutasidenib).
-
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
6/1/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL , and virtually.
-
Rigel to Present at the Jefferies 2023 Global Healthcare Conference
5/31/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m. ET at the Jefferies 2023 Global Healthcare Conference, being held June 7-9, 2023 in New York, NY.
-
Rigel Reports First Quarter 2023 Financial Results and Provides Business Update
5/2/2023
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
4/28/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2023.
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
4/25/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2, 2023.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - April 06, 2023
4/6/2023
Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/7/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022.